Glitches in Co-WIN are minor, new system to work like RAC: R S Sharma

R S Sharma, who chairs the empowered committee on technology for Covid vaccine, spoke to Nivedita Mookerji on what went wrong with Co-Win during the first few days, the scale-up exercise, and more

R S Sharma
R S Sharma, Chairman, empowered committee on technology for Covid vaccine
Nivedita Mookerji New Delhi
4 min read Last Updated : Jan 20 2021 | 6:10 AM IST
Many states have raised concerns over technology glitches in the vaccination delivery platform Co-WIN. R S Sharma, who chairs the empowered committee on technology for Covid vaccine, spoke to Nivedita Mookerji on what went wrong with Co-Win during the first few days, the scale-up exercise, plans for a flexible system, vaccine hesitancy, and more. Edited excerpts:          

How has it been going for you as chairman of the technology platform (Co-WIN) for Covid vaccine?

I entered the system (in the newly appointed panel for Co-WIN) on January 9. I have reviewed the system and found small software glitches, which we are removing. But we have to scale up the software to cover up to 1.3 billion — which is one-sixth of humanity.  Nobody has done this kind of a thing on the planet.

What really went wrong in the first three days with Co-WIN that many states had to go manual with the vaccine tracking and delivery process?

They were minor glitches; I will give you an example. Ultimately, the vaccines are limited… You have, for instance, invited some 100 people for vaccination at a centre and perhaps only 20 turned up. For a variety of reasons, many didn’t turn up. 

The system was designed in such a manner that if 100 were invited, they would all come and get vaccinated, and there would be another list the next day, and so on. When that didn’t happen, glitches occurred. 

Now we have to make the system flexible to accommodate people who have registered for today, tomorrow, and the day after… The new system will be like RAC (reservation against cancellation used widely in the railways) and people on the wait list will be accommodated for vaccination when the scheduled beneficiaries don’t turn up.  We didn’t have that flexibility for the first few days.

So, how do you go about making the system robust?

We have to do it in a way that’s citizen-centric. That is, from vaccinating only health workers, we have to roll it out for much larger numbers in future. There’s no doubt that this is the largest programme in the world. Through Co-Win, we are designing a system which is scalable and which is citizen-friendly. Self-registration will be introduced so that people can mention when and at which place they want to be vaccinated closer home. While Aadhar infrastructure will help in authenticating the process, digital certificates—provisional or final--will be given once vaccination is done.

What else needs to be done?

We plan to eliminate any information asymmetry. Registration can be done through multiple channels including Aarogya Setu app, mobile phone, helpline or on the web. Right now, we are dealing with a captive audience—health and frontline workers. That system is scaling up and adding new components like real time dashboard and information system.

What is the broad objective of the panel that you are chairing?

I’m responsible for making a robust technology platform and backbone to ensure vaccination is transparent, traceable, citizen-friendly and that there’s no information asymmetry. That’s the broad objective and we will ensure that. Certain things are non-negotiable. For instance, real time recording of the vaccination event is very important because that’s the only way we can follow up with people later on. Also, people should authenticate themselves so that there’s no room for proxy. So, we are focusing on a robust authentication of system, recording of real time events and immediate issuance of certificate.

There’s very little information on the technology backend of Co-Win. Who owns it and who operates it? Are there any IT companies managing it?

We are doing it and the strategic ownership is with the government of India. Software developers may be there but the overall ownership is with the government.

Who in the government manages it? Is it NIC (National Informatics Centre)?

I have created a group now with people from NIC and other government departments who will take ownership of Co-Win.

You are also a member of the National Expert Group on Vaccine Administration of Covid-19. What’s your assessment of the vaccine hesitancy mood in India?

There’s a lot of fake news on risks and adverse effects of vaccination. That has created some fear in the minds of people. I think that’s completely baseless. The initial anxiety will go away and people will go for vaccination with confidence I’m sure. That’s my sense. Of course it’s a subjective thing.

Is the government doing anything to build citizen trust in vaccine?

The government is telling the truth while some people are doing campaigns against vaccines saying they are not safe, etc.

What about the Covaxin versus Covishield debate that is going on?

This is beyond my domain (laughs). As doctors have already said, both are absolutely safe.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineR S SharmaSerum Institute of IndiaBharat BiotechFake newsVaccineVaccination

Next Story